Vaccinex, Inc. (VCNX) is a pioneer company utilizing modern approach against oncological diseases. The lead product candidate of the company is pepinemab which has the potential to cure different cancers as well as Alzheimer’s disease and osteosarcoma. VX5 is another potential candidate for therapeutic potential against autoimmune diseases.
The price of VCNX stock during the regular trading on January 25, 2022 was $1.02 with a slight increase of 0.99%. At last check in the current market, the stock was further up by 22.5%.
VCNX: Events and Happenings
On January 26, 2022, VCNX reported optimistic response results for the KEYNOTE-B84 safety trials of pepinemab. The company collaborated with KEYTRUDA therapy of Merck for this purpose. The study was conducted on patients with head and neck squamous cell cancer.
VCNX: CEO Comments
Speaking at the occasion, VCNX CEO Maurice Zauderer said that by merging pepinemab with KEYTRUDA will decrease the chances of the process of chemotherapy. He further added that the company is looking forward to share further optimistic outcomes at a conference.
On November 10, 2021, VCNX reported about the management’s poster presentation for pepinemab effect on patients. The poster was presented at the 36th Annual Meeting of Society for Immunology of Cancer on November 12-14, 2021. On November 09, 2021, VCNX reported about presentation of Executives at the Clinical Trials on Alzheimer’s Disease Meeting on November 11, 2021.
VCNX: Key Financials
On November 08, 2021, VCNX reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.
Revenue and Assets
Revenue in Q3 2021 was $0.05 million versus $0.6 million in the same period of 2020. The total current assets in third quarter 2021 were recorded to be $14.8 million.
Net Loss per Share
Basic and diluted net loss per share in Q3 2021 was $5.2 million or $0.17 against $8.7 million or $0.44 in same period prior year.
Conclusion
VCNX didn’t performed well during the last six months period as the company’s stock fell 56% during that time. The current premarket stock boom is the consequence of complete responses in the patients regarding KEYNOTE-B84 studies. The financial specialists are optimistic that the company is outperforming to attract potential investment.
